European Medicines Agency consults on five-year strategy

Regulator’s development plan reflects broader EU pharmaceutical strategy

The European Medicines Agency, the EU’s regulator of medical treatments, is inviting feedback on a draft five-year strategy that includes a shift to more post-licensing data collection and innovations in the regulatory process.

Some of the most research-relevant parts of the EMA consultation, which opened on 6 July and closes on 4 September, include a push for more academic collaborations in the field of regulatory science, and research on the process of regulation itself.